265 completed, 103 terminated, 93 unknown, 46 recruiting. 341 Phase 2, 134 Phase 1, 114 Phase 3, 16 Not applicable, 9 Phase 4.
Follow Xeloda: new trials by email Literature Review of Xeloda trials Research Report on Xeloda
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial of Pembrolizumab With Chemotherapy or Chemoradiotherapy in Participants From India With Different Types of Cancer (MK-3475-G44/KEYNOTE-G44) Pembrolizumab, Cisplatin, 5-Fluorouracil - Neoplasm Malignant, Gastric Neoplasms | Phase 4 | Not yet recruiting | Merck Sharp & Dohme LLC | 150 | 2026-11-06 | 2026-09-03 |
| Combining DCSZ11 With Radiation and Chemotherapy as Neoadjuvant Treatment for pMMR Locally Advanced Rectal Cancer DCSZ11, Radiation, Capecitabine - Rectal Cancer | Phase 2 | Not yet recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 30 | 2026-11-01 | 2026-10-28 |
| Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer Oxaliplatin, Capecitabine, Cemiplimab - Colorectal Cancer | Phase 2 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 66 | 2026-07-14 | 2026-07-21 |
| Zanidatamab Combined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positive (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a Phase II Open-Label Study Zanidatamab, Oxaliplatin, Capecitabine - Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | Phase 2 | Not yet recruiting | Zhifeng Zhao, PhD | 46 | 2026-07-01 | 2026-07-06 |
| Vasodilator Therapy With Isosorbide Mononitrate or Diltiazem to Reduce Vasotoxicity in Patients With Gastrointestinal Cancer Receiving Fluoropyrimidine Therapy Biospecimen Collection, Capecitabine, Diltiazem Hydrochloride - Malignant Digestive System Neoplasm | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 60 | 2026-04-30 | 2026-06-02 |
| PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA) Capecitabine, Elacestrant - Estrogen-receptor-positive Breast Cancer, Metastatic Breast Cancer | Phase 2 | Recruiting | Kristina A. Fanucci | 297 | 2026-01-16 | 2026-08-26 |
| Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction and Gastric Cancers Capecitabine, Docetaxel, Fluorouracil - Clinical Stage I Gastric Cancer AJCC v8, Clinical Stage II Gastric Cancer AJCC v8 | Phase 1 | Withdrawn | Ohio State University Comprehensive Cancer Center | 2025-12-31 | 2025-02-07 | |
| ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer Evorpacept (ALX148), Trastuzumab, Paclitaxel - Breast Cancer, Metastatic | Phase 2 | Recruiting | ALX Oncology Inc. | 120 | 2025-12-10 | 2026-09-25 |
| SCRT-NALIRIXELOX+Sintilimab as TNT for High-Risk LARC SCRT, Liposomal Irinotecan, Oxaliplatin - Rectal Cancer, Adenocarcinoma | Not applicable | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 49 | 2025-11-30 | 2026-03-16 |
| A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine, Capecitabine, Computed Tomography - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma | Phase 2 | Recruiting | University of Washington | 40 | 2025-11-17 | 2026-11-02 |
| Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer Tislelizumab, Oxaliplatin, Capecitabine - Colonic Neoplasms, Neoadjuvant Therapy | Phase 3 | Not yet recruiting | First Affiliated Hospital of Guangxi Medical University | 94 | 2025-10-01 | 2025-08-20 |
| Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer Biospecimen Collection, Bone Scan, Capecitabine - Anatomic Stage IV Breast Cancer AJCC v8, Estrogen-receptor-positive Breast Cancer | Phase 2 | Recruiting | Mayo Clinic | 35 | 2025-10-01 | 2026-08-12 |
| Consolidation of Toripalimab and Capecitabine After Chemoradiotherapy in ESCC toripalimab, capecitabine - Esophageal Cancer, Chemoradiotherapy | Phase 3 | Recruiting | Sun Yat-sen University | 242 | 2025-09-10 | 2026-04-21 |
| DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment Fluorouracil injection, Xeloda - Colorectal Neoplasms, Breast Neoplasms | Phase 4 | Recruiting | Rutgers, The State University of New Jersey | 100 | 2025-08-27 | 2025-11-13 |
| Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer Biopsy Procedure, Biospecimen Collection, Capecitabine - Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8 | Phase 3 | Recruiting | NRG Oncology | 356 | 2025-08-21 | 2026-08-25 |
| FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery Balstilimab, Biospecimen Collection, Botensilimab - Rectal Adenocarcinoma, Stage IIA Rectal Cancer AJCC v8 | Phase 2 | Recruiting | City of Hope Medical Center | 26 | 2025-05-20 | 2026-06-29 |
| Phase II Single Arm Trial of Low Dose Capecitabine in Patients With Advanced Breast Cancer Capecitabine Pill - Metastatic Breast Cancer | Phase 2 | Recruiting | University of Alabama at Birmingham | 40 | 2025-02-14 | 2026-09-30 |
| Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer Trastuzumab deruxtecan, Capecitabine, Rilvegostomig - Stomach Neoplasms | Phase 2 | Recruiting | Jeeyun Lee | 100 | 2025-01-22 | 2026-07-01 |
| Comparing the Efficacy of Sintilimab Plus Nab-POF Regimen, Sintilimab Plus XELOX Chemotherapy, and Lenvatinib, Sintilimab Plus XELOX Chemotherapy in the Treatment of HER2-negative, Metastatic Gastric Cancer Sintilimab, oxalipaltin, 5FU,Nab-paclitaxel,lenvatinib - Gastric (Stomach) Cancer | Phase 2 | Not yet recruiting | Fudan University | 141 | 2024-12-25 | 2024-12-27 |
| A Study of Tetrathiomolybdate (TM) Plus Capecitabine Tetrathiomolybdate, Capecitabine, Pembrolizumab - Triple Negative Breast Cancer, Residual Disease | Phase 1 / Phase 2 | Recruiting | Dartmouth-Hitchcock Medical Center | 204 | 2024-11-26 | 2026-04-20 |
Showing 20 of 563. Sign in to see all of them.
Breast Neoplasms (135) · Colorectal Neoplasms (90) · Rectal Neoplasms (80) · Stomach Neoplasms (65) · Pancreatic Neoplasms (62) · Neoplasm Metastasis (40) · Neoplasms (31) · Colonic Neoplasms (30) · Triple Negative Breast Neoplasms (21) · Esophageal Neoplasms (15) · Biliary Tract Neoplasms (13) · Adenocarcinoma (11) · Carcinoma, Hepatocellular (8) · Gastrointestinal Neoplasms (8) · Nasopharyngeal Carcinoma (8)
National Cancer Institute (NCI) (33) · Hoffmann-La Roche (32) · M.D. Anderson Cancer Center (29) · Fudan University (23) · Sun Yat-sen University (16) · Hellenic Oncology Research Group (9) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (9) · Columbia University (7) · ECOG-ACRIN Cancer Research Group (7) · University of Washington (7) · Dana-Farber Cancer Institute (6) · H. Lee Moffitt Cancer Center and Research Institute (6) · Spanish Breast Cancer Research Group (6) · IRCCS San Raffaele (5) · SCRI Development Innovations, LLC (5)
United States (276) · China (101) · Spain (44) · South Korea (42) · France (38) · Italy (38) · Germany (35) · Canada (31) · Belgium (26) · United Kingdom (26) · Taiwan (23) · Australia (21) · Austria (21) · Brazil (20) · Greece (19)
Michele Reni, MD (5) · Christopher H. Crane, MD (4) · John Souglakos, MD (4) · Alexander de Vries, MD (3) · Dimitris Mavrudis, MD (3) · Dung Le, MD (3) · Norman Wolmark, MD (3) · Robert L Fine, MD (3) · Thomas Yau, MD (3)
PMID 34037241, PMID 20728210, PMID 29804905, PMID 36306483, PMID 37957132, PMID 39863139, PMID 10918161, PMID 11248153, PMID 15496622, PMID 15668283, PMID 15691639, PMID 16079161, PMID 16098249, PMID 16236737, PMID 16479065, PMID 16606972, PMID 17042060, PMID 17208639, PMID 18407737, PMID 18422971, PMID 18441328, PMID 18502088, PMID 18506163, PMID 19073506, PMID 19104202, PMID 19106287, PMID 19164203, PMID 19505212, PMID 19525947, PMID 19636002, PMID 19732686, PMID 19906561, PMID 20048179, PMID 20163987, PMID 20165987, PMID 20209610, PMID 20351330, PMID 20375404, PMID 20461379, PMID 20680680, PMID 20797891, PMID 21047409, PMID 21098710, PMID 21135251, PMID 21267531, PMID 21285134, PMID 21295551, PMID 21298494, PMID 21475011, PMID 21874317
U10CA180820 (9), U10CA180868 (7), U10CA032102 (6), 2005 (4), 2008 (4), 2023 (4), P30CA036727 (4), U10CA021115 (4), 2016 (3), U01CA062491 (3), U10CA021661 (3), 2004 (2), 2014 (2), 2015 (2), 2018 (2)